In this review:
This review is a summary of the pharmacological and clinical characteristics of dolutegravir (Tivicay®), which is an orally-administered integrase strand transfer inhibitor (INSTI) approved for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in adults and children aged >12 years and weighing ≥40kg.Expert commentary on the use of dolutegravir from a clinical practice perspective is provided by Dr Rupert Handy (ADHB).
Download PDF